雷贝拉唑联合康复新液治疗Ⅱ、Ⅲ级反流性食管炎40例临床观察

目的：观察雷贝拉唑联合康复新液治疗Ⅱ、Ⅲ级反流性食管炎的临床疗效及安全性。方法：79例Ⅱ、Ⅲ级反流性食管炎患者随机分成两组，观察组40例给予雷贝拉唑胶囊10mg，pobid，康复新液10ml,po tid；对照组39例仅予雷贝拉唑胶囊10mg，pobid治疗。疗程均为8周。观察两组患者的临床疗效、治疗前后临床症状评分、胃镜下食管炎改善情况及药品不良反应。结果：两组患者治疗后症状评分较治疗前明显下降（P〈0．001），观察组下降较对照组更为明显（P〈0．01）；按临床症状疗效判定，观察组显效率明显高于对照组（P〈0．05）；按胃镜检查疗效判定，观察组显效率（P〈0．01）及总有效率（P〈0．05）均较对照组显著增高。两组不良反应少。结论：雷贝拉唑联合康复新液治疗Ⅱ、Ⅲ级反流性食管炎疗效优于单一使用雷贝拉唑，且安全性好。

Clinical Observation of the Treatment of Reflux Esophagitis with Rabeprazole Combined with Kangfuxin Liquid

Objective： To investigate the effects and safety of rabeprazole and kangfuxin liquid on reflux esophagitis. Methods：79 cases with reflux esophagitis were randomly divided into observation group （n =40） and control group （n = 39）. The patients in the control group received their oral rabeprazole 10mg, twice a day and patients in the observation group took rabeprazole plus kangfuxin liquid 10ml, 3 times a day for a course of eight weeks. The clinical efficacy, clinical symptom scores before and after the treatment, endoscopic esophagitis improvement situation and adverse reactions were ob- served and compared between the two groups. Results ：The clinical symptom scores after the treatment were more obviously decreased than those before the treatment （P 〈 0.001 ）, but the decrease in the observation group was more significant than that in the control group with statistical difference （ P 〈 0.01 ）. The clinical marked efficacy of the observation group was higher than that of the control group（72.5% vs 48.7%, P 〈 0.05 ）. Endoscopic efficiency comparison, the marked effica- cy（ 80.0% vs 51.3%, P 〈 0.01 ） and the total efficacy （ 100.0% vs 87.2%, P 〈 0.05 ） of the observation group were higher than those of the control group too, but the drug adverse effect was less. Conclusion： For reflux esopbagitis, the therapeutic effect of rabeprazole plus kangfuxin liquid was superior to that of rabeprazole only with higher safety, and it had no increased drug adverse reaction .